Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
Conditions: Childhood Central Nervous System Choriocarcinoma; Childhood Central Nervous System Embryonal Tumor; Childhood Central Nervous System Germ Cell Tumor; Childhood Central Nervous System Germinoma; Childhood Central Nervous System Mixed Germ Cell Tumor; Childhood Central Nervous System Teratoma; Childhood Central Nervous System Yolk Sac Tumor; Metastatic Childhood Soft Tissue Sarcoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Central Nervous System Embryonal Tumor; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Childhood Visual Pathway Glioma; Unspecified Childhood Solid Tumor, Protocol SpecificInterventions: Drug: pazopanib hydrochloride; Other: pharmacological studySponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)Active, not recruiting - verified December 2012
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain Stem Giloma | Brain Tumor | Cancer & Oncology | Choriocarcinoma | Embryonal Carcinoma | Germ Cell Tumors | Glioma | Research | Sarcomas | Soft Tissue Sarcoma | Teratoma